Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment

Type 2 diabetes mellitus (T2DM) has a high prevalence and incidence around the world. The complex pathophysiology mechanism is among the barriers for diabetes treatment. Type 2 diabetes patients have dysfunction in incretin hormones (as glucagon-like peptide-1 or GLP-1, and glucose-dependent insulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Guedes, Erika Paniago, Hohl, Alexandre, de Melo, Thais Gomes, Lauand, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667107/
https://www.ncbi.nlm.nih.gov/pubmed/23697612
http://dx.doi.org/10.1186/1758-5996-5-25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667107/
https://www.ncbi.nlm.nih.gov/pubmed/23697612
http://dx.doi.org/10.1186/1758-5996-5-25

Ejemplares similares